The Eugin Group appoints Marcio Fernandes as CEO and reports €100 million in revenue following structural changes

The assisted reproduction clinic group Eugin has entered a new phase of growth, supported by a renewed executive leadership team. The company has appointed Marcio Fernandes as Chief Executive Officer, succeeding Luis Ángel Varela. Meanwhile, Ignacio Valledor will take over leadership of the business in Spain and Portugal.

These appointments follow significant changes in the group's ownership. In 2023, the German group Fresenius, the former owner of Eugin, initiated a divestment process. As a result, IVI RMA acquired Eugin's operations in the United States and Canada, while Spanish investment fund Buenavista Equity Partners (formerly GED Capital) took over operations in nine markets across Europe and Latin America—now the scope of Eugin's current business.

Under the new ownership, Eugin is entering a phase of consolidation and stabilization, according to Fernandes and Valledor. Fernandes, who has been with Eugin for eight years, initially joined the company through its entry into Brazil with the acquisition of Huntington centers. He first led the company's operations in Latin America and later assumed global operational leadership. Prior to joining Eugin, he served as CFO at Dasa, a leading medical diagnostics company in Latin America.

Valledor, who replaces Rafael Fraile as CEO for Spain and also serves as Eugin's Chief Marketing Officer, brings over 20 years of experience in the digital health sector, with previous roles at Clínica Baviera and Sanitas. He also founded Healthia, a startup acquired by a major insurer in 2017.

Following the restructuring of its business scope, Eugin reported provisional revenues of approximately €100 million in 2024 and achieved an 18% EBITDA margin in its key markets. For 2025, the company expects to grow organically by 8% and increase its gross profit by double digits.

The group's current strategy focuses on strengthening its position in its most important markets, including Spain, Brazil, Italy, and Sweden. In Italy, the company has recently expanded into new areas. Valledor also highlighted the company’s efforts to enhance collaboration among its subsidiaries, noting that initiatives in Brazil could positively impact operations in Spain.

Eugin currently employs around 1,000 people across 34 clinics. Its Barcelona headquarters houses the largest assisted reproduction center in Europe, spanning 6,000 square meters and featuring 30 rooms.

New acquisitions under consideration

Over the last decade, Eugin has pursued both national and international growth through acquisitions. In Spain, the group acquired CIRH Clinic and FecunMed; in Brazil, it purchased Huntington; and in Colombia, it partnered with Medifértil. After a period of paused corporate transactions, Fernandes confirmed that the company is once again evaluating opportunities for inorganic growth, which are seen as complementary to its organic expansion plans.

Another key focus area is investment in research and development. Eugin has recently launched several R&D initiatives, including the development of an artificial intelligence system designed to predict the success of fertility treatments.

Read more HERE.